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Abstract
Background: Normal tissue homeostasis is maintained by dynamic interactions between epithelial cells and their
microenvironment. Disrupting this homeostasis can induce aberrant cell proliferation, adhesion, function and migration that
might promote malignant behavior. Indeed, aberrant stromal-epithelial interactions contribute to pancreatic ductal
adenocarcinoma (PDAC) spread and metastasis, and this raises the possibility that novel stroma-targeted therapies
represent additional approaches for combating this malignant disease. The aim of the present study was to determine the
effect of human stromal cells derived from adipose tissue (ADSC) on pancreatic tumor cell proliferation.
Principal Findings: Co-culturing pancreatic tumor cells with ADSC and ADSC-conditioned medium sampled from different
donors inhibited cancer cell viability and proliferation. ADSC-mediated inhibitory effect was further extended to other
epithelial cancer-derived cell lines (liver, colon, prostate). ADSC conditioned medium induced cancer cell necrosis following
G1-phase arrest, without evidence of apoptosis. In vivo, a single intra-tumoral injection of ADSC in a model of pancreatic
adenocarcinoma induced a strong and long-lasting inhibition of tumor growth.
Conclusion: These data indicate that ADSC strongly inhibit PDAC proliferation, both in vitro and in vivo and induce tumor
cell death by altering cell cycle progression. Therefore, ADSC may constitute a potential cell-based therapeutic alternative
for the treatment of PDAC for which no effective cure is available.
Citation: Cousin B, Ravet E, Poglio S, De Toni F, Bertuzzi M, et al. (2009) Adult Stromal Cells Derived from Human Adipose Tissue Provoke Pancreatic Cancer Cell
Death both In Vitro and In Vivo. PLoS ONE 4(7): e6278. doi:10.1371/journal.pone.0006278
Editor: Irene Oi-Lin Ng, The University of Hong Kong, Hong Kong
Received February 24, 2009; Accepted May 31, 2009; Published July 17, 2009
Copyright:  2009 Cousin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work has been supported by grants from Region Midi-Pyrenees, Ligue Nationale Contre le Cancer and Cancrople Grand Sud-Ouest (EMERGEANCE).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: beatrice.cousin@inserm.fr
Introduction
Normal tissue homeostasis is maintained by dynamic interac-
tions between epithelial cells and their microenvironment. The
microenvironment consists of extracellular matrix, stromal cells,
migratory immune cells and neural elements supported by a
vascular network, all within a milieu of cytokines and growth
factors. Cells interact with the microenvironment via complex
autocrine and paracrine mechanisms. Multiple evidences show
that disrupting this homeostasis can induce aberrant cell
proliferation, adhesion, function and migration that might
promote malignant behavior [1–3]. Recent studies have altered
the perception of the stromal cells surrounding epithelial tumors.
These cells are not idle bystanders, but rather active participants
that shape the frequency and features of the tumors. In addition,
cancer cells themselves can alter their adjacent stroma to form a
permissive and supportive environment for tumor progression
[1–3].
Cancer stem cells and stromal fibroblasts are extensively
demonstrated to support neoplastic process [4–11], when bone
marrow derived mesenchymal stem cells (BM-MSCs) indirectly
favor tumor growth following systemic immunosuppression [12],
or production of pro-angiogenic cytokines [13–15]. However, the
effects of BM-MSCs on tumor proliferation vary according to the
tumor type: BM-MSCs promote breast, melanoma and colon
cancer derived cells proliferation [16,17], when inhibit the in vivo
growth of Kaposi’s sarcoma cells [18]. Adipose tissue, like bone
marrow, contains stromal cells called ADSCs for Adipose-derived
Stromal Cells. This population shares many of the characteristics
of the BM-MSCs, including immunomodulatory effects [19], and
multilineage differentiation potentials [20–29]. Once injected in
vivo, ADSCs exhibit regenerative properties either by direct
participation in newly formed tissues and/or via production of
growth factors that sustain this regeneration [23,25,30]. Although
stromal cells from bone marrow and adipose tissue seem to be
closely related, notable differences were reported [19,31–34]. The
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largely debated. In vitro, expanded ADSCs mediated suppression of
allogeneiclymphocyte proliferation[35]. Contradictoryresults were
obtained in vivo, when co-injection of ADSCs with breast, colon,
prostate, non-small lung or glioblastoma cancer-derived cells led to
initial tumor growth support [36–38]. To clarify such discrepancy,
we studied the effect of ADSCs on pancreatic ductal adenocarci-
noma-derived cells. Among solid tumors, pancreatic ductal
adenocarcinoma (PDAC) is characterized by its extremely dense
desmoplastic infiltration [39,40]. PDAC is a highly aggressive
disease with no therapeutic solution, and still the fifth leading cause
of cancer-related deaths in Western countries [41]. Because
aberrant stromal-epithelial interactions contribute to PDAC spread
and metastasis, we hypothesize that targeting the tumor stroma may
represent an additional approach for treating PDAC. Here, we
demonstrate the ability of human ADSCs (hADSCs) to reduce
PDAC-derived cancer cells growth, in vitro and in vivo, and to induce
cancer cell death following G1-phase arrest.
Results
Human ADSCs exert an inhibitory effect on PDAC-
derived cell lines
First, hADSC phenotype was determined by flow cytometry
(Supplementary Text S1) in order to confirm that the cells used
displayed phenotypic characteristics usually described for ADSCs
[22,23]. Indeed, FACS analyses confirmed that ADSC were CD34,
CD90, CD73 and HLA ABC positive whereas CD45 and CD31
negative (Supplementary Figure S1). We then determined the in vitro
effect of hADSCs on PDAC tumor cell growth. We cultured PDAC-
derived Capan-1 cells in the presence of ADSCs isolated from 25
different healthy donors using transwell membranes to prevent cell-
to-cell contact. After 48 hours of co-cultures, ADSC exhibited a
potent dose-dependent inhibitory effect on PDAC-derived cell
number, as demonstrated in figure 1A. Indeed, the number of
pancreatic cancer cells was significantly decreased by 36.5%64.8%
in the presence of 1:1 ratio of ADSCs, when compared to the control.
Conditioned medium from ADSCs inhibits the viability of
many tumor cells
The absence of direct cell–to-cell contact in our experimental
setting prompted us to test whether ADSCs-conditioned medium
(CM) may also impair cancer-cell viability. Indeed, soluble factors
have been previously demonstrated to mediate the immunosuppres-
sive effect of human ADSCs [19]. As shown in figure 1B, ADSC-CM
by itself significantly inhibited not only the viability of several
pancreatic adenocarcinoma-derived cells (Capan-1, Capan-2, BxPC3,
Miapaca-2), but also the viability of hepatocarcinoma-derived cells
(HuH7, HepG2), of colon-cancer-derived cells (Caco-2), and of
prostate cancer cell line (PC3). In contrast, ADSC culture supernatant
had little, if any, effect on Hela cells derived from cervical cancer or
MCF-7, a breast cancer cell line. Because, the observed responses may
reflect depletion of nutrients from media and/or non specific
accumulation of toxic metabolites, we used conditioned medium
from cancer cells alone as a control, together with BM-MSC-CM. In
contrast to ADSC-CM, treating cancer cells with either Capan-1 or
BM-MSC-CM did not impair significantly cancer cell viability
althoughatrend ofdecreasewasobservedwiththelastone(figure1C).
ADSC-conditioned medium inhibits tumor cell
proliferation and induces tumor cell death
To analyze potential effect of ADSC-CM on cancer cell
proliferation, Capan-1 were incubated in presence of BrdU with
or without ADSC-CM. FACS analysis was performed after cell
denaturation and incubation with propidium iodide. BrdU is
incorporated during S phase (gate P4) whereas staining with
propidium iodide allows discrimination between 2n (G0/G1, gate
P2) and 4n (G2/M, gate P3) chromosomes (Figure 2A). Dot plots
gated on single cells showed that the number of Capan-1 cells in
G0/G1 phase tended to increase when cells in S phase
significantly decreased by 10% in the presence of ADSC-CM
(figure 2B).
We next determine whether ADSC-CM could affect cell death.
To this end, we first monitored DNA fragmentation in Capan-1
cells by TUNEL assay. As shown in figure 2C, PDAC-derived cell
DNA fragmentation was strongly induced by ADSC-CM. We next
quantified the number of cancer cells entering apoptosis and/or
necrotic following exposure to ADSC-CM. Results presented
figure 2D demonstrate that ADSC-CM induced a 3-fold increase
in propidium iodide-positive, necrotic cells, without evidence of
early apoptosis monitored by annexin labeling. Again, CM from
BM-MSC was ineffective in altering significantly tumor cell
viability (data not shown).
Tumor cell death induced by ADSC conditioned medium
is mediated by inhibition of cell cycle progression
We next investigated the mechanism by which tumor cell cycle
is arrested by ADSC-CM. We measured the expression of the
main proteins involved in cell cycle regulation. We found that
ADSC-CM induced a profound inhibition of Rb phosphorylation
in Capan-1 cells, with no effect on the protein expression
(figure 3A, 3B). Noticeably expression of CDK4 and Cyclin D1,
which are critical for Rb phosphorylation, decreased concomi-
tantly. Expression of Cyclin E, which is not involved in the G1-S
transition, remained unchanged (Figure 3A; 3B). Of importance,
no changes were found in the expression levels of cleaved caspase-
3, caspase-8, caspase-9, caspase-6, caspase-7, and PARP following
treatment of the cells with ADSC-CM (data not shown). Also,
expression levels of cytochrome C, BclXl and Bcl2 remained
relatively unchanged in our experimental settings (data not
shown).
ADSCs reduce the in vivo growth of human pancreatic
tumors
We next extended ADSCs antiproliferative activities to the
inhibition of pancreatic tumors, in vivo. Thus, human PDAC
tumors were established in athymic mice following the subcuta-
neous injection of Capan-1 cells as a very aggressive model of
PDAC [42,43]. Fourteen to seventeen days following tumor
engraftment, a single dose of ADSCs, corresponding to 10
3
ADSCs/mm
3 of tumor was transferred in vivo into growing tumors.
Control tumors were injected either with vehicle or with
paraformaldehyde (PFA) fixed ADSCs. Control tumors grew
rapidly, averaging 40766556 mm
3 in size by 28 days following
implantation (figure 4A, 4B). In contrast, growth of Capan-1
tumors receiving ADSC injection was strongly inhibited
(25566232 mm
3; figure 4A, 4B). Inhibition of pancreatic tumor
growth progression reached 258%68.9% (p,0.001), two weeks
after a single intratumoral injection of ADSCs (figure 4C). Tumor
weight was also significantly reduced after ADSCs implantation
(control: 4,6 g60.8 vs ADSCs-treated 2.2 g60.2, p,0.05). As
shown in figure 4D, growth of tumors injected with either vehicle
or PFA-treated ADSCs were comparable, showing that the
inhibition of tumor growth was not due to an unspecific effect of
tumor dilacerations and dependent on ADSC secretion, respec-
tively.
Antitumor Effect of Human ADSC
PLoS ONE | www.plosone.org 2 July 2009 | Volume 4 | Issue 7 | e6278Figure 1. Human ADSCs induce a contact-independent inhibition of tumor cells growth and viability. A. Increasing ratios of ADSC and
Capan-1 cells were co-cultured in the presence of transwell for 48 hours in full growth media. Capan-1 cells proliferation was then quantified by cell
counting. Values are means6S.E. of three separate experiments with ADSCs from different donors. B. Cancer cells from diverse origins were cultured
in the presence of ADSC conditioned medium (CM) for 48 hours. Cell viability was ascertained by MTS using The CellTiter 96H AQueous One Solution
Cell Proliferation Assay. Results are expressed as percentage of values obtained in control conditions. Values are means6S.E. of three separate
experiments performed with ADSC-CM from different donors. C. Capan-1 cells were cultured for 48 h with Capan-1, BM-MSC or ADSC-CM. Capan-1
cell number was quantified as in A. Values are means6S.E. of three separate experiments with ADSCs and MSCs from different donors. *: p,0.05. ***;
p,0.001.
doi:10.1371/journal.pone.0006278.g001
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PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6278Figure 2. Human ADSCs inhibit cell proliferation and induce cell death in pancreatic cancer cells. A. Capan-1 cells were cultured with or
without ADSCs conditioned medium was added. 48 hours later, proliferation and DNA content were analyzed by flow cytometry using BrdU
incorporation and propidium iodide as described in Material and Methods. Dot plots are representative of 3 independent experiments performed
with ADSCs sampled from different donors. B. Quantification of cell-cycle analysis using ModFit software. Capan cultured in control conditions were
represented in black bars in contrast to Capan treated with ADSC-CM represented in open bars. Values are means6S.E. of three separate experiments
with ADSCs from different donors. C. Capan-1 cells were seeded in 4-chamber slides for 48 h with or without ADSC-CM. DNA fragmentation was
measured by TUNEL (representative of three separate experiments). D. Capan-1 cultured in control medium (black bars) or treated with ADSC
supernatants (open bars) were assayed for Annexin and propidium iodide labelling as described in Material and Methods. Values are means6S.E. of
three separate experiments with ADSCs from different donors. ***: p,0.001.
doi:10.1371/journal.pone.0006278.g002
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human ADSCs on PDAC tumors in vivo. Tumors treated or not
with ADSCs were processed for immunohistochemistry for the
nuclear antigen Ki67 in order to detect proliferating cells
(figure 4E, top panel), or processed for TUNEL analysis to
quantify dead cells (figure 4E, bottom panel), 6 days following
injection. Quantification of immunostaining demonstrated a
significant decrease in the number of proliferating cells, in
ADSCs-transferred tumors when compared to control
(266.5%63.8%; p,0.01). In addition, ADSCs induced a 5-fold
increase in cell death in pancreatic tumors as measured by
TUNEL assay.
Discussion
We demonstrated in the present study that human ADSCs
sampled from a large panel of different healthy donors efficiently
impaired the growth of a very aggressive cancer, i.e. PDAC, both
in vitro and in vivo by inhibiting cancer cell proliferation and
promoting cancer cell death following G1-phase block. The latter
inhibitory effect was extended to malignant cell lines from diverse
origins.
Several of our in vitro observations reported here demonstrate
that ADSCs have the ability to interfere with the proliferation of
tumor cells by altering cell cycle progression. The in vitro molecular
data showed that tumor cells that had been in contact with ADSC-
CM were in a resting state (G0/G1), and down regulated CDK4
and cyclinD1. Interestingly, we were unable to identify either
extrinsic or intrinsic-mediated cell death by apoptosis following
exposure of cancer cells to ADSCs conditioned medium. This
ability to interfere with cell cycle has already been described for
stromal cells from other origins [44,45]. Abnormalities of G1-S
transition regulators, and more specifically of the Rb pathway,
have been recognized as significant factors in the development of
human cancers. Consequently, modulation of CDK is a major
target for tumor prevention and therapy that may explain why
ADSCs inhibit the proliferation of cells derived from multiple
epithelial cancers.
The use of ADSC as vehicle in cancer gene therapy has been
recently proposed [36,46,47]. Indeed ADSCs engineered to
convert anticancerous prodrug may be efficient vehicles to
potently inhibit the growth of xenografted human colon or
prostate tumors [36,46]. However, only a few studies showing
conflicting results have been conducted with naı ¨ve cells isolated
from adipose tissue [36–38,48]. These discrepancies may be
explained by the process of ADSC isolation and passage, the
number of injected cells and the procedures used for in vivo or in
vitro studies. Indeed, in some studies, ADSC were injected in vivo
together with the cancer cells, it is thus difficult to compare the
effects of ADSC on installed tumor (in this study) versus growing
tumor [36–38]. In addition, some data were obtained with mouse
cells [38] whereas our model is made of human cells, and cancer
cells from diverse origins were used, although we demonstrated
that ADSC-CM did not affect tumor cell viability in the same
extent. Last and not least, the nature of ADSC varies according to
the different studies, since in most cases passaged cells were used
[36–38,48] whereas we performed experiments with primary
cultures. This may be of importance as ADSC phenotype and
potentially function are modified with passages [49]. This
variability in the potential effects of stromal cells on cancer cell
proliferation has also been described in studies using bone marrow
mesenchymal stem cells [16–18], suggesting that different
mechanisms may be involved according to several factors that
remain to be identified. For example, we demonstrate here that
cell to cell contact is not fully necessary as anti-proliferative effects
were observed both in direct co-culture studies using transwell (no
cell contact) and in experiments using ADSCs conditioned
medium. In contrast, Khakoo et al recently demonstrated that
BM-MSCs exerted a potent antioncogenic effect on Kaposi’s
sarcoma through cell to cell contact and Akt inactivation [18].
This was later on confirmed in vitro by Ramasamy et al [45].
The identification of the mechanisms involved in stromal and
cancer cells interactions and especially the secreted factor
responsible for the anti-proliferative effect of ADSC is currently
Figure 3. Mechanism of tumor cell cycle arrest by ADSC-CM. A.
Capan-1 cells were cultured with or without ADSC-CMfor 48 hours.
Proteins were then extracted and subjected to immunoblotting for the
indicated proteins as described in Material and Methods. Results are
representative of at least 3 independent experiments. B. Quantification
of immunoblot densitometry in control cultures (black bars) or cultures
treated with ADSC-CM (open bars). Values are means6S.E. of three
separate experiments with ADSCs from different donors. *: p,0.05; **:
p,0.01.
doi:10.1371/journal.pone.0006278.g003
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TGF b1, SDF1, RANTES), interleukines (such as IL6, IL1 b, IL8,
GSF, IL11) or prostaglandins (PGE2, PGI2, PGJ2) are known to
exert an anti-proliferative/pro-apoptotic effect. Migratory studies
performed with Capan revealed that ADSC-CM present no
chemoattractant activity (Supplementary Figure S2, and text S1),
Figure 4. Intratumoral delivery of human ADSCs inhibits pancreatic cancer cell proliferation and induces cell death in vivo. Capan-1
tumors were implanted into athymic nude mice (four to six animals per group) as described in Material and Methods. Two weeks later, ADSC were
injected within the tumor, and the progression was then monitored. A. Representative resected tumors from athymic nude mice 15 days after
receiving no treatment (left) or a single intratumoral dose of 5610
5 ADSCs (right). B. The volume of control (black symbols) or ADSC treated (open
symbols) tumors was monitored every 2 days, up to 28 days following implantation (13 days following ADSCs injection). C. Percentage of control
(black bars) or ADSC treated (open bars) tumor progression was measured at the time indicated following in vivo ADSCs injection. D. Tumors were
injected either with vehicle, PFA fixed ADSCs or ADSCs and their progression was measured 6 days following intratumoral cell delivery. E. Histological
sections of pancreatic tumors injected or not with ADSC were analyzed for proliferation by Ki67 immunostaining (Ki67 labeling index, top panel) or
for DNA fragmentation by TUNEL assay (bottom panel), 6 days following ADSC injection. The percentage of labeled nuclei was measured in 15 fields
at high magnification (6400) using the visiolab 2000 analysis system. All results were representative of 3 to 4 independent experiments (3 to 5 tumors
per group) performed with ADSCs sampled from different healthy donors. Values are means6S.E. *: p,0.05; **: p,0.01; ***: p,0.01.
doi:10.1371/journal.pone.0006278.g004
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effect is not a chemokine. Recently, PGs have been demonstrated
to mediate ADSCs mixed lymphocyte reaction inhibition [35].
During the preparation of this manuscript, a study proposed that
DKK-1 may be one of these factors (48). IL-6 has been recently
involved in protecting normal and premalignant epithelial cells
from apoptosis in colitis associated cancer (50). This suggests that
this interleukin may play opposite roles depending upon the
inflammatory status, the tumor stage and/or type.
In vivo, we obtained a yet effective, but transient anti-
proliferative effect on tumor progression. GFP-labeled ADSCs
were detected surrounding peripheral tumor vessels and within
central and peripheral acellular and necrotic areas of the tumor,
up to 5 days following injection (Supplementary Figure S3 and
Text S1). Based on this observation, the concentration and/or the
half-life of the soluble factors responsible for the anti-proliferative/
anti-tumoral effect are probably not sufficient to maintain tumor
cells in a quiescent state for a long time, but are adequate to
initially antagonize cancer cell proliferation. Such transitory effect
may be rescued by multiple, intratumoral injection of ADSCs.
Delivering human cells into a mouse xenografted with human
cancer cells might result in a non-specific xenogenic immune
response within the recipient to counteract in vivo tumorigenesis.
However, because (i) Capan-1 cells do not express MHC from
class I and II (data not shown), and (ii) athymic mice immune
system (only mediated by NK cells) is less important than in
immune animals, we reasonably exclude a non-specific immune
response in the observed effect. Considering the ability of ADSC
to participate in vascular-like structure formation [23], we cannot
rule out a specific pro-angiogenic effect of ADSC in the context of
pancreatic tumor growth. However, this effect, if any, seems to be
minor at the stage of the disease, i.e. during the exponential phase
of tumor growth as we tested in this work. In addition, we were
unable to identify changes in vascular density, either from mouse
or human origin, following intratumoral injection of ADSCs (data
not shown). Alternative changes in ADSCs phenotype following
intratumoral injection should be carefully monitored. Indeed, we
recently showed that ADSCs rapidly and massively acquired high
phagocytic activity and index, when injected into the peritoneal
cavity of nude mice [51].
Altogether, our work represents the first study using non-
engineered cells to treat PDAC. This anti-proliferative effect of
ADSC on pancreatic cancer cells is mediated at least in part by a
secreted factor but it is also tempting to speculate that in vivo
ADSC may modify the microenvironment of the tumor and thus
inhibit its proliferation. In conclusion, ADSCs ability to block G1-
S phase transition and subsequently to inhibit of cancer cells
proliferation in vitro and in vivo may be an efficient and feasible
approach for the treatment of the 85% of PDAC patients that
cannot be operated in a curative way due to a locally advanced
disease.
Materials and Methods
Ethic Statement
Human adipose tissue was obtained as waste from aesthetic
surgery procedures. All patients gave their written consent. The
procedures were approved by the regional ethic committee
‘‘Comite ´ de protection des personnes Sud Ouest et Outre Mer I’’.
Chemicals
For adipose tissue digestion, collagenase was purchased from
Roche (Roche Diagnostic, Germany). Bovine serum albumin
(BSA), dexamethasone, ascorbate-2 phosphate, pantothenic acid,
and insulin-transferrin-sodium selenite supplement were pur-
chased from Sigma Aldrich (St. Quentin Fallavier, France). Foetal
calf serum (FCS), trypsin, DMEM, RPMI-1640, fungizone,
penicillin, streptomycin, and PBS were provided by Invitrogen
(Cergy-Pontoise, France). Foetal bovine serum (FBS) for ADSC
culture was purchased from Perbio (Paris, France). The anti-
mycoplasma agent, Plasmocin
TM was provided by InvivoGen
(Toulouse, France).
Tumor cell culture
Capan-1, Capan-2, BxPC-3, Miapaca-2 and Panc-1 cell lines
derived from human PDAC were cultured as described before
[52]. HuH7 and HepG2 cells, derived from hepatocellular
carcinoma, were cultured as described elsewhere [53]. PC3
(human prostate cancer) and Caco-2 cells (human colon
carcinoma) were cultured in DMEM 1 g/l glucose medium
supplemented with 10% FCS. Hela (human cervical carcinoma),
were cultured in DMEM 4,5 g/l glucose medium supplemented
with 10% FCS. All media were supplemented with fungizone,
antibiotics, L-Glutamine, and antimycoplasma reagent (Plasmo-
cin
TM, InvivoGen). Cells were kept at 37uC and 5% CO2.
Human ADSCs preparation and culture
Human ADSCs were sampled from 20 healthy donors. Stroma
vascular fraction was isolated from human adipose tissue obtained
from abdominal dermolipectomy in the plastic surgery department
of Rangueil Hospital (Toulouse, France) as previously described
[19]. Briefly, SVF cells were plated in T75 flasks overnight in
DMEM-F12 (1:1) medium supplemented with 5% FBS, 100 mg/
ml pantothenic acid, 100 mM ascorbic acid, 16 mM biotin,
250 mg/ml amphotericin, 5 mg/ml streptomycin and 5 U/ml
penicillin. After 24 h, cultures were washed extensively using
PBS to remove residual non-adherent cells. HADSC growth was
pursued until cells reached 75% confluence (passage 0).
In vitro cell number assessment
50610
3 Capan-1 cells were cultured in complete RPMI
medium for 24 h in 35-mm dishes, before serum starvation for
16 hours. Cells were cultured in triplicate in the presence or not of
ADSCs or BM-MSCs conditioned medium for another 48 hours.
Control cells were cultured in DMEM-F12 (1:1) medium
supplemented with 5% FBS. Cell growth was measured by cell
counting using a Coulter counter model ZM. For co-culture
assays, Capan-1 cells were first plated in cell culture inserts with
4 mm pores (BD biosciences) in complete medium for 24 h. After a
16 h deprivation step, Capan-1 cells were transferred into 35-mm
dishes in the presence of ADSCs at different ratios. All
experiments were conducted with ADSCs and MSCs purified
from different healthy donors.
In vitro cell viability assay
Target cells (15610
3) were cultured in complete medium in flat-
bottom 96-well plates for 24 h, before serum starvation for
16 hours. Cells were cultured in triplicate in the presence or not of
ADSC-conditioned medium for another 48 hours. Control cells
were cultured in DMEM-F12 (1:1) medium supplemented with
5% FBS. Cell viability was measured by MTS assay, according to
the manufacturer recommendations (CellTiter96 AQueous Assay,
Promega France, Charbonnieres, France). Experiments were
conducted with ADSCs purified from different healthy donors.
Results are expressed as percentage of values obtained in control
conditions.
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Capan-1 cells were cultured and treated with ADSCs-CM as
described in ‘‘in vitro cell number assessment’’ section. Cells were
incubated with BrdU 10 mM (Sigma Aldrich) for 4 h at 37uC.
Capan were collected, washed once in PBS then fixed in ice-cold
70% ethanol 1 h at 4uC. Cells were collected by centrifugation at
600 g, washed in PBS containing BSA 0.5% and Tween-20 0.5%,
and resuspended in HCl 2N and incubated for 30 min at room
temperature. After washing, cells were suspended in sodium borate
buffer (0.1 M, pH 9) to neutralize residual acid. Cells were stained
with anti-BrdU monoclonal antibody (Becton Dickinson) for
30 min at room temperature. After washings, Capan-1 cells were
resuspended in propidium Iodide staining solution (5 mg/ml)
before analysis on flow cyotmeter (CantoII, Becton Dickinson). For
annexin-V and propidium iodide detection, Cells were labelled
with either annexin-FITC (Apoptotest FITC, DakoCytomation),
or propidium iodide (Invitrogen) as per the manufacturer’s
recommendation. Apoptotic and necrotic cells were quantified
using a BD FACS Calibur (Beckton Dickinson) and Cell quest pro
software (Beckton Dickinson).
TUNEL assays
Detection of cell death by TUNEL assay on Capan-1 tumors
was done as described elsewhere [42]. For In vitro cell-death assays,
50610
3 Capan-1 cells were seeded in in 4-well glass slides (Lab-
Tek II chamber slide, Nalge Nunc International, Naperville IL) in
complete medium for 24 h. After serum starvation for 16 hours,
cells were cultured in triplicate in the presence or not of ADSC-
CM for another 48 hours. Control cells were cultured in DMEM-
F12 (1:1) medium supplemented with 5% FBS. Detection of the
early stages of the chromosome breakdown was performed using
Apopdetek, following manufacturer recommendations (ApopDE-
TEK, Enzo life sciences, Farmingdale, NY, USA).
Western Blot analysis
Proteins were extracted from Capan-1 cells, resolved on SDS-
polyacrylamide gels, and transferred to nitrocellulose membrane
as described elsewhere [53]. After room-temperature blocking for
1 h, blots were incubated with antibodies purchased from Santa
Cruz Biotechnology, Inc (Heidelberg, Germany) raised against
cyclinD1 (sc-124), CDK4 (sc-260), CyclinE (sc-247), bactin (sc-
8432) or glyceraldehydes-3-phosphate dehydrogenase (GAPDH)
(sc-24778). Rb and phosphospecific Rb antibodies were from Cell
signaling Technology (Ozyme, St Quentin en Yvelines, France).
Secondary HRP-conjugated antibodies (Perbio Science, Erem-
bogdegem-Aalist, Belgium) were added, and blots were incubated
for 1 h at room temperature. Immunoreactive proteins were
visualized using ECL immunodetection system (Immobilon,
Millipore Corporation, Billerica, MA 01821, USA).
In vivo model of pancreatic cancer
The in vivo model of xenografted PDAC-derived cells into athymic
mice has been extensively described elsewhere [42]. Briefly, 5610
6
exponentially growing Capan-1 cells (100 mlP B S )w e r ei n o c u l a t e d
subcutaneously (s.c.) into 8-week-old athymic female nude mice
(Swiss nude/nude; IFFA-CREDO, l’Abresle, France) bred and
maintained in pathogen-free conditions. On days 14 and 17 following
xenograft, intratumoral in vivo cell transfer of 10
3 ADSCs/mm
3 of
tumor was performed with a sterile, 29G insulin needle. As a control,
tumors were injected with vehicle or paraformaldehyde (PFA)-
treated cells. Each experimental group comprised three to five
animals. Four sets of transfer experiments were conducted, with
ADSCs sampled from different healthy donors. Tumor size was
monitored up to 28 days following transfer as reported elsewhere
[42]. At the time of experiment completion, mice were sacrificed;
tumors were sampled and frozen in liquid nitrogen or fixed in
formalin for further immunohistochemical studies
Immunostaining for Ki67 in pancreatic tumors
Capan-1 tumors were harvested and fixed in formalin. Four-
micrometer-thick sections were prepared from paraffin-embedded
sections and rehydrated as described elsewhere [42]. Following
antigen retrieval, sections were incubated for 10 min in Protein
Block, Serum-free reagent (DakoCytomation) to reduce back-
ground staining. Slides were next incubated overnight at 4uC with
anti-Ki67 antibody, (1:100 Clone MIB-1, DakoCytomation).
Antibody incubations were done in Dako Antibody diluent
(DakoCytomation). After 3 washes in PBS, slides were incubated
in 3% H2O2 for 30 min at room temperature to inhibit
endogenous peroxydase. Slides stained for Ki67 were quickly
rinsed in distilled water, before 2 washes in PBS, and incubated for
30 minutes at room temperature with biotinylated rabbit anti-
mouse IgG (DakoCytomation) and HRP-conjugated streptavidin
ABC complex (DakoCytomation) following the manufacturer’s
instructions. Immunolabeling was visualized with AEC detection
reagent (DakoCytomation). After washing in distilled water, slides
were counterstained with Mayer’s hematoxylin. Resulting immu-
nostaining was observed with an optical microscope, and
quantified using VisioLab2000 image analyzer (Biocom, France).
For each group, 15 fields were analyzed.
Statistical analysis
Results are expressed as mean6standard error (SE). One way
Anova test or unpaired t-test were calculated using Graphpad
Instat software, and used to compare data (*: p,0.05, **: p,0.01;
***:p,0.001). p,0.05 was considered significant.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0006278.s001 (0.04 MB
DOC)
Figure S1 Flow cytometry analysis of ADSC phenotype. ADSC
phenotype was analyzed by flow cytometry using a combination of
cell surface markers. Dot plots representative of 6–10 different cell
cultures showed homogeneous population positive for stromal cell
markers (CD34, CD90, HLA-ABC, CD73) and negative for
hematopoietic (CD45) and endothelial (CD31) cell surface markers.
Found at: doi:10.1371/journal.pone.0006278.s002 (0.08 MB TIF)
Figure S2 ADSC conditioned media present no chemoattrac-
tant activity on Capan-1 cells. Chemotactic migration of Capan-1
cells was performed as described in Suplementary methods, with
three different ADSC-conditioned media. A. Quantification of
chemotaxis (chemotactic index) is calculated by chemotaxis/
spontaneous migration. Values are means6S.E. of three separate
experiments. B. Pattern of migration in response to control
medium. C. Pattern of migration in response to ADSC
conditioned medium. B and C are representative of three
independent expriments.magnifications 64.
Found at: doi:10.1371/journal.pone.0006278.s003 (0.25 MB TIF)
Figure S3 GFP-labeled ADSC are readily detected in pancreatic
tumors following intratumoral injection. Capan-1 tumors were
implanted into athymic nude mice as described in Materials and
Methods. hADSC transduced with a lentiviral vector encoding for
GFP were injected intratumorally. 5 days later, tumors were
sampled, fixed in paraformaldehyde and analyzed for GFP
Antitumor Effect of Human ADSC
PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6278expression. GFP expression was detected by immunochemistry as
described in Suplementary Methods in control-injected (A) and
ADSC-injected samples (B, C). Results are representative of three
tumors injected with GFP- labeled hADSC. magnification 6400.
Found at: doi:10.1371/journal.pone.0006278.s004 (0.31 MB TIF)
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